Ardelyx, Inc. ARDX
Set alert
3.03 USD 0.00 0.00%
At close · Nov 2
3.03 0.00 0.00%
After hours · Nov 2, 5:27 PM ET
2.98 Day range 3.09
2.96 52-week range 8.40
- YTD
- -48.03%
- 1 year
- -50.00%
- Open
- 3.00
- Prev close
- 3.03
- Mkt cap
- 782.31M
- Vol
- 4.60M
- Avg vol
- 4.58M
- EPS
- -0.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.98
- High
- 3.09
- Forward P/E
- 15.44
- Beta
- 0.73
- Short ratio
- 8.72
- Inst. own
- 73.33%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Oct 29, 2026
- 50-d avg
- 5.09
- 200-d avg
- 5.97
- 1y target
- 12.90
6M chart
Events in this range
- Aug 6, 2026Earnings: -0.07; estimate -0.06545; surprise -6.95%
- Aug 7, 2026Rating: BTIG · Buy → Buy
- Aug 7, 2026Rating: TD Cowen · Buy → Buy
- Aug 10, 2026Rating: Citigroup · Buy → Buy
- Aug 17, 2026Rating: Piper Sandler · Overweight → Overweight
- Aug 18, 2026Rating: Wedbush · Outperform → Outperform
- Aug 19, 2026Rating: Wedbush · Outperform → Outperform
- Oct 29, 2026Earnings: —; estimate -0.03; surprise —%
Signals (22)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 12, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 7, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 10, 2026 | 1 month ago |
| RSI: Oversold | Sep 3, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 7, 2026 | 2 months ago |
| RSI: Oversold | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 23, 2026 | 3 months ago |
| MACD: Sell Signal | Jun 29, 2026 | 4 months ago |
| SMA: Bearish | Jun 25, 2026 | 4 months ago |
| SMA: Bearish | Jun 23, 2026 | 4 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 16, 2026 | 4 months ago |
| SMA: Bearish | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| SMA: Bearish | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 13, 2026 | 5 months ago |
| MACD: Sell Signal | May 13, 2026 | 5 months ago |
| RSI: Overbought | May 4, 2026 | 6 months ago |
Key statistics
- Market cap
- 1.00B
- Enterprise value
- 972.51M
- Trailing P/E
- 0.00
- Forward P/E
- 15.44
- PEG ratio
- 0.00
- Price / sales
- 2.23
- Price / book
- 6.51
- EPS (TTM)
- -0.23
- Beta
- 0.73
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -12.35%
- Revenue (TTM)
- 450.89M
- Revenue growth
- 23.80%
- Free cash flow
- 20.47M
- Total cash
- 281.83M
- Total debt
- 282.51M
- Return on equity
- -38.61%
- Shares outstanding
- 258.19M
- Short % of float
- 10.76%
- 50-day average
- 5.09
- 200-day average
- 5.97
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 12.90 +325.7% upside
Now 3.03
- Target (low)
- 8.00
- Target (mean)
- 12.90
- Target (high)
- 18.00
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy1
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 29, 2026
Expected Oct 29, 2026. Consensus EPS estimate -0.01863.
Financials — quick view
ARDX Revenue — quarterly 120.88M
ARDX Net income — quarterly -16.72M
ARDX EPS — quarterly -0.07
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2026 | Sep 30, 2026 | -0.03 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.06545 | -0.07 | 0.00 | -6.95% |
| Apr 30, 2026 | Mar 31, 2026 | -0.13 | -0.15 | -0.02 | -15.38% |
| Feb 19, 2026 | Dec 31, 2025 | 0.02 | 0.02 | 0.00 | 0.00% |
| Oct 30, 2025 | Sep 30, 2025 | -0.06 | -0.00401 | +0.06 | +93.32% |
| Aug 4, 2025 | Jun 30, 2025 | -0.13 | -0.08 | +0.05 | +38.46% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 19, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 18, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 17, 2026 | Piper Sandler | main | Overweight | Overweight |
| Aug 10, 2026 | Citigroup | main | Buy | Buy |
| Aug 7, 2026 | TD Cowen | main | Buy | Buy |
| Aug 7, 2026 | BTIG | main | Buy | Buy |
About Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ardelyx.com
News
- ARDELYX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
- ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
- Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
- ARDX Shareholder Alert: Ardelyx, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
- Kaplan Fox Announces the Lead Plaintiff Deadline of November 16, 2026 in the Securities Class Action Against Ardelyx, Inc. (ARDX)
- ARDELYX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
- ARDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026
- Ardelyx Deadline: ARDX Investors with Losses in Excess of $100K Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit
- ARDELYX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
- ARDELYX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
Your note
Sign in to keep a note on ARDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERTRAND WILLIAM C JR | Director | Stock Award(Grant) | Jun 15, 2026 | 329,507 |
| BISHOP JOHN E | Officer | Sale | May 20, 2026 | 336,845 |
| FOSTER ERIC DUANE | Officer | Sale | May 20, 2026 | 417,972 |
| KELLIHER MICHAEL | Officer | Sale | May 20, 2026 | 357,418 |
| MOTT DAVID M | Director | Stock Award(Grant) | Jun 15, 2026 | 3,349,660 |
| RAAB MICHAEL G | Chief Executive Officer | Sale | Jul 14, 2026 | 1,703,730 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.43% | 23,504,630 | 91.43M | Jun 29, 2026 |
| Rubric Capital Management LP | 6.50% | 16,202,700 | 63.03M | Jun 29, 2026 |
| Millennium Management Llc | 5.58% | 13,900,773 | 54.07M | Jun 29, 2026 |
| State Street Corporation | 5.36% | 13,356,128 | 51.96M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.20% | 10,471,494 | 40.73M | Jun 29, 2026 |
| Nomura Asset Management International Inc | 3.83% | 9,546,732 | 37.14M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.97% | 7,404,867 | 28.80M | Mar 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.97% | 7,389,361 | 28.74M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.57% | 6,400,256 | 24.90M | Jun 29, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 2.51% | 6,265,909 | 24.37M | May 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.08% | 2,702,696 | 10.51M | Mar 30, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.96% | 2,392,375 | 9.31M | May 30, 2026 |